Italia markets close in 1 hour 44 minutes

Merck KGaA (MRK.DE)

XETRA - XETRA Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
150,15-2,20 (-1,44%)
In data: 03:30PM CEST. Mercato aperto.

Merck KGaA

Frankfurter Strasse 250
Darmstadt 64293
Germany
49 6151 72 0
https://www.emdgroup.com

Settore/iHealthcare
SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno62.908

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Ms. Belen Garijo Lopez M.D.Chair of Executive Board & CEO6,62MN/D1960
Ms. Helene von RoederCFO & Member of Executive Board1,23MN/D1970
Dr. Kai BeckmannCEO of Electronics & Member of the Executive Board4,85MN/D1965
Mr. Peter GuenterCEO of Healthcare Business & Member of Executive Board5,58MN/D1962
Dr. Matthias J. HeinzelCEO of Life Science Sector & Member of Executive Board5,22MN/D1967
Ms. Barbara WeilandChief Compliance OfficerN/DN/D1974
Mr. Dietmar EidensHead of the Global HR Business Partner OrganizationN/DN/D1958
Mr. Frank GotthardtHead of Corporate & Government Relations - EuropeN/DN/DN/D
Mr. Marc HornHead of Life Science ControllingN/DN/D1975
Dr. Michael HeckmeierHead of the Display Materials Business Unit for Performance MaterialsN/DN/D1967
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Governance aziendale

L'ISS Governance QualityScore di Merck KGaA al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 10; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.